C07J 7/0015
Not substituted in position 17 alfa
Official title: {not substituted in position 17 alfa}
C07J7/0015 (Not substituted in position 17 alfa) appears on 208 US grants and 251 published applications in this corpus.
Search patents in C07J- Granted patents
- 208
- Published applications
- 251
- Assignees
- 115
- Inventors
- 458
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 8 | 0 |
| 1978 | 2 | 0 |
| 1979 | 3 | 0 |
| 1980 | 5 | 0 |
| 1981 | 6 | 0 |
| 1982 | 3 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 3 | 0 |
| 1990 | 6 | 0 |
| 1991 | 4 | 0 |
| 1992 | 5 | 0 |
| 1993 | 5 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 4 | 0 |
| 2000 | 5 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 1 |
| 2004 | 1 | 4 |
| 2005 | 1 | 1 |
| 2006 | 1 | 2 |
| 2007 | 1 | 1 |
| 2008 | 1 | 1 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 2 |
| 2013 | 3 | 6 |
| 2014 | 2 | 13 |
| 2015 | 2 | 9 |
| 2016 | 7 | 14 |
| 2017 | 12 | 23 |
| 2018 | 6 | 13 |
| 2019 | 19 | 20 |
| 2020 | 8 | 18 |
| 2021 | 7 | 29 |
| 2022 | 15 | 17 |
| 2023 | 10 | 20 |
| 2024 | 12 | 24 |
| 2025 | 8 | 16 |
| 2026 | 3 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders21 Jul 2026US 12,686,700 B2Sage Therapeutics, Inc.
- C17, C20, and C21 substituted neuroactive steroids and their methods of use16 Jun 2026US 12,655,175 B2Sage Therapeutics, Inc.
- Compositions and methods for treating CNS disorders27 Jan 2026US 12,534,495 B2Sage Therapeutics, Inc.
- Neurosteroid compounds and methods for their preparation and use in treating central nervous system disorders30 Dec 2025US 12,509,487 B2The Texas A&M University System
- Process for preparing (3α,5α)-3-hydroxy-3-methyl-pregnan-20-one (Ganaxolone)9 Dec 2025US 12,492,221 B2Industriale Chimica S.R.L.
- Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders8 Oct 2026US 2026/0308198 A1Sage Therapeutics, Inc.
- Lymph directing prodrugs24 Sep 2026US 2026/0284004 A1Monash University
- Neurosteroids and Prodrugs Thereof24 Sep 2026US 2026/0285897 A1Emory University
- Regio-controllable [2+2] benzannulation with two adjacent c(sp3)-h bonds20 Aug 2026US 2026/0242341 A1The Scripps Research Institute
- Neuroactive steroids, compositions, and uses thereof30 Apr 2026US 2026/0116911 A1Sage Therapeutics, Inc.
Most cited
By later US patents
- Orally administrable form of progesterone127US 4,196,188 A1980
- Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series74US 5,939,545 ACoCensys, Inc. · 1999
- Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series70US 5,232,917 AUniversity of Southern California · 1993
- Methods for allosteric modulation of the GABA receptor by members of the androstane and pregnane series62US 6,277,838 B1CoCensys, Inc. · 2001
- Chemical compounds60US 4,192,871 AGlaxo Laboratories Limited · 1980